Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Kim Pfotenhauer DO, FACOFP

Kim Pfotenhauer DO, FACOFP

Assistant Professor of Family Medicine; Diabetologist; Assistant Dean for Clerkship Education, Michigan State University College of Osteopathic Medicine, East Lansing, Michigan

Kim Pfotenhauer, DO, FACOFP, is a Board Certified Osteopathic Family Physician and a Fellowship trained Diabetologist. She is currently the Assistant Dean for Clerkship Education and an Assistant Professor at Michigan State University College of Osteopathic Medicine. She serves as National Faculty for the NBOME, on the board of the Michigan Association of Osteopathic Family Physicians, and on the American Diabetes Association Primary Care Advisory Group. She previously served on the American Diabetes Association Women’s Interprofessional Network Advisory Group where she helped develop the WIN ADA Professional Development Course. She is also a founding board member and currently the Public Relations Chair of the American College of Diabetology. She has worked on educational initiatives with the American College of Osteopathic Family Medicine, the Endocrine Society, and the American Diabetes Association. Speaking regionally and nationally on diabetes, nonalcoholic fatty liver disease and vitamin D, she focuses on empowering primary care physicians to improve patient metabolic health.

Disclosures

Dr. Pfotenhauer is a consultant for Abbott Laboratories and Novo Nordisk.